Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grignani

Showing results (541-550 of 688) with videos related to

Pageof 69
Sort By:
ESMO Open|August 28, 2020
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre studyAnastasia Constantinidou, Nicolas Sauve, Silvia Stacchiotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphomaU Vitolo, S Cortellazzo, A M Liberati, et al.
Frontiers in Cardiovascular Medicine|January 20, 2022
Electrocardiographic and Echocardiographic Insights From a Prospective Registry of Asian Elite AthletesTee Joo Yeo, Mingchang Wang, Robert Grignani, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
European Journal of Radiology Open|July 24, 2023
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)Giovanni Cappello, Valentina Giannini, Roberto Cannella, et al.
The Lancet. Oncology|December 16, 2014
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialGiovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, et al.
Acta Oncologica (Stockholm, Sweden)|November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysisA Kollár, R L Jones, S Stacchiotti, et al.
Genes, Chromosomes & Cancer|March 20, 2019
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GISTMilena Urbini, Valentina Indio, Giuseppe Tarantino, et al.
International Journal of Cancer|July 26, 2021
Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle EastPaolo Antonio Ascierto, Kristina Orlova, Giovanni Grignani, et al.
Therapeutic Advances in Medical Oncology|September 6, 2018
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenibBruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, et al.
Pageof 69

Showing results (541-550 of 688) with videos related to

Sort By:
Pageof 69
ESMO Open|August 28, 2020
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre studyAnastasia Constantinidou, Nicolas Sauve, Silvia Stacchiotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphomaU Vitolo, S Cortellazzo, A M Liberati, et al.
Frontiers in Cardiovascular Medicine|January 20, 2022
Electrocardiographic and Echocardiographic Insights From a Prospective Registry of Asian Elite AthletesTee Joo Yeo, Mingchang Wang, Robert Grignani, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
European Journal of Radiology Open|July 24, 2023
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)Giovanni Cappello, Valentina Giannini, Roberto Cannella, et al.
The Lancet. Oncology|December 16, 2014
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialGiovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, et al.
Acta Oncologica (Stockholm, Sweden)|November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysisA Kollár, R L Jones, S Stacchiotti, et al.
Genes, Chromosomes & Cancer|March 20, 2019
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GISTMilena Urbini, Valentina Indio, Giuseppe Tarantino, et al.
International Journal of Cancer|July 26, 2021
Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle EastPaolo Antonio Ascierto, Kristina Orlova, Giovanni Grignani, et al.
Therapeutic Advances in Medical Oncology|September 6, 2018
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenibBruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, et al.
Pageof 69